BostonGene, a leader in AI-driven molecular and immune profiling solutions, has announced a new research collaboration with Takeda focused on immuno-oncology. This partnership aims to enhance clinical solutions and patient outcomes by pinpointing key molecular drivers and predictive markers of treatment response and adverse events.
Under this collaboration, Takeda will leverage BostonGene’s AI-based multi-omics platform in early-stage clinical trials. The platform will help refine clinical trial design, improve indication selection, and identify biomarkers for response and toxicity. BostonGene will conduct advanced multi-omics analysis and bioinformatics, processing data from flow cytometry, RNA sequencing, and proteomics provided by Takeda.
“We are excited to partner with BostonGene to advance oncology research using cutting-edge technology,” said PK Morrow, MD, Head of Takeda’s Oncology Unit. “This collaboration aims to leverage data and AI to gain deeper insights into the biology of therapeutic drugs, which will help us better understand their potential in specific patient populations and contribute to developing effective cancer treatments.”
Nathan Fowler, M.D., Chief Medical Officer of BostonGene, expressed enthusiasm about the partnership, noting that the advanced multi-omics analysis will enhance patient selection and identify key mechanistic signatures associated with treatment responses, thus advancing innovative therapies.
About BostonGene Corporation
Founded in 2015, BostonGene combines technology and biology to advance and personalize cancer care. The company uses its AI-driven multi-omics analytics platform to digitize and thoroughly characterize the molecular profiles of cancer patients, including their immune systems and tumor microenvironments. BostonGene’s software solutions and advanced bioanalytics facilitate the discovery and targeting of multi-parameter signatures, which are matched to relevant indications to recommend the most effective treatments.
